Analystreport

Summit Therapeutics (NASDAQ: SMMT) was upgraded by analysts at Zacks Investment Research from a "strong sell" rating to a "hold" rating.

Summit Therapeutics Inc.  (SMMT) 
Last summit therapeutics inc. earnings: 6/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre